20120126.LumB
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.380
- PROTEIN_SECRETION+0.360
- G2M_CHECKPOINT+0.340
- OXIDATIVE_PHOSPHORYLATION+0.320
- DNA_REPAIR+0.310
- E2F_TARGETS+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
- ANDROGEN_RESPONSE+0.220
- SPERMATOGENESIS+0.220
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- TNFA_SIGNALING_VIA_NFKB-0.480
- INFLAMMATORY_RESPONSE-0.460
- INTERFERON_ALPHA_RESPONSE-0.450
- HEDGEHOG_SIGNALING-0.440
- IL6_JAK_STAT3_SIGNALING-0.440
- INTERFERON_GAMMA_RESPONSE-0.440
- ALLOGRAFT_REJECTION-0.380
- KRAS_SIGNALING_UP-0.350
- MYC_TARGETS_V2-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20040104.LumB | — | B | 0.885 |
| 2 | 20050151.LumB | — | B | 0.867 |
| 3 | DRR168570 | — | — | 0.866 |
| 4 | TCGA-E2-A15K-06A-11R-A12P-07 | — | B | 0.858 |
| 5 | SRR1516049 | — | — | 0.854 |
| 6 | AUR-AFE4-TTM6-A-1-1-R-A742-41 | — | C | 0.849 |
| 7 | MNG1070 | — | — | 0.846 |
| 8 | SAMN03290953 | — | — | 0.844 |
| 9 | SAMN03290941 | — | — | 0.843 |
| 10 | TCGA-E2-A1IE-01A-11R-A13Q-07 | — | B | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |